Table 1.

Genetic polymorphisms involved in clinicopathological characteristics of leukemia/lymphoma.

CD markers	Chr.	Biologic role	SNP	Region/Allele	Disease	Population	Method	Effect	Ref.
CD33	19q13.4	Sialic acid-binding receptor	rs12459419	Exon 2 C>T; Ala14Val	AML	American	PCR	Higher OS and decreased expression of CD33	4
			rs1803254	3'-UTR G>C
			rs2455069	(A>G); Arg69Gly	AML			Higher relapse risk and low OS
CD44	11p13	Involved in cell-cell interactions, cell adhesion and migration	rs35112940	Exon 6 (AA+ AG)
CD185	11q23.3	Involved in B-cell migration into B-cell follicles of spleen and Peyer’s patches	rs13347	promoter	AML	Chinese	Western Blot	May be a genetic modifier for developing AML	9
					HL, NHL, AML	Poland	PCR	Associated with poor mobilization of HSCs	11
			rs6421571	Intron	NHL	Chinese	PCR–RFLP	Increased susceptibility to NHL and development of disease toward high Ann Arbor stage (III + IV) stage	14
			rs80202369					Associated with increased susceptibility to NHL
			rs1790192	Intron	NHL, FL, DLBCL,	Iowa	PCR	Associated with increased risk of malignancies and better event-free survival of FL patients.	15
					PTCL

AML, acute myeloid leukemia; OS, overall survival; FL, follicular lymphoma; DLBCL, diffuse large B-cell lymphoma; PTCL, peripheral T-cell lymphoma; HL, Hodgkin lymphoma; NHL, non- Hodgkin lymphoma; HSC, hematopoietic stem cells; PCR, polymerase chain reaction; PCR-RFLP, polymerase chain reaction-restriction fragment length polymorphism.